Ofev Cost 2026: Real Prices and How to Save
Ofev Cost 2026: Real Prices and How to Save
Your pulmonologist writes the prescription, the specialty pharmacy calls to "verify benefits," and then someone reads you a number that sounds like a used car. Twelve thousand dollars. Per month.
That's not a billing error. Ofev cost has sat above $10,000 a month since it came to market in 2014, and for most of that time there was nothing anyone could do about it. That changed in 2026 — generic nintedanib finally cleared the FDA in April, and Medicare has negotiated a price that takes effect next January. Most of the pages you'll find online haven't caught up to either fact.
At a glance
- Brand-name Ofev carries a 2026 list price of about $12,600 per month for the standard 150 mg twice-daily dose, with retail cash prices reported between $13,475 and $16,019.
- That's roughly $151,000 a year for one prescription.
- Generic nintedanib was FDA-approved in April 2026 — Apotex, Cipla, Dexcel, Dr. Reddy's, and Sandoz all won approval, and US launches are underway.
- Medicare negotiated a Maximum Fair Price of $6,350 per month for Ofev, a 49.7% cut, effective January 1, 2027 — but that applies to Medicare Part D, not to cash payers.
- Cash-pay and cross-border prices for nintedanib have been listed as low as roughly $500 to $1,500 a month, a fraction of US specialty pharmacy pricing.
How much does Ofev cost per month without insurance?
Ofev (nintedanib) is a specialty medication, which means you can't walk into a corner pharmacy and pick it up. It's dispensed through a limited network of specialty pharmacies, and that channel sets the price you see.
Here's what a 30-day supply — 60 capsules, the standard 150 mg twice-daily regimen — costs in 2026 depending on where the prescription is filled:
| Where you buy | Approximate cash price (30-day supply, 60 capsules) |
|---|---|
| Manufacturer list price (2026) | ~$12,600 |
| Drugs.com reported retail (100 mg) | ~$13,475 |
| Blink Health listed price | ~$13,578 |
| GoodRx reported average retail | ~$16,019 |
| GoodRx coupon price (select versions) | ~$980 |
| Cross-border / international listings | ~$500–$1,500 |
The spread between the top and bottom of that table is more than $15,000 a month for the same molecule. That's not a rounding difference. It's the difference between filling the prescription and not filling it.
One detail worth knowing: Ofev is priced almost identically at 100 mg and 150 mg. If your doctor reduces your dose for tolerability or liver enzymes, your symptoms may improve — but your bill won't be cut in half. You're paying per capsule, and you still take two a day.
Annualized, brand-name Ofev at list runs about $151,000. For a medication people take indefinitely, for a disease that doesn't go into remission, that number is the whole problem.
Is there a generic for Ofev?
Yes — and this is the single biggest change in Ofev pricing in a decade.
In April 2026, the FDA approved generic nintedanib esylate capsules in both 100 mg and 150 mg strengths from multiple manufacturers, including Apotex, Cipla USA, Dexcel Pharma Technologies, Dr. Reddy's Laboratories, and Sandoz. Several announced they were launching immediately through specialty distribution channels.
If you read a cost article that says Ofev "is available only as a brand-name medication" with "no generic alternatives," it was written before April 2026 and hasn't been updated. Several of the highest-ranking pages on this topic still say exactly that.
What generic entry means for your actual price is a fair question, and the honest answer is: it depends on how fast the market moves. Multiple approved manufacturers competing at once usually pushes prices down hard, but specialty distribution slows the drop compared with a drug you'd pick up at Walgreens. Early cash prices for generic nintedanib have been inconsistent from pharmacy to pharmacy.
For a sense of where this can land, look at the other IPF drug.
What happened to Esbriet is the roadmap
Esbriet (pirfenidone) is the other approved treatment for idiopathic pulmonary fibrosis, and it went through this exact transition a few years earlier.
Brand Esbriet still runs about $10,215 for 270 tablets of the 267 mg strength — roughly a month's supply at the full dose. Generic pirfenidone for the same quantity: about $597. With a discount coupon, some pharmacies have quoted as little as $213 for that same 270-tablet supply.
That's a 94% drop from brand to generic, and better than 97% off retail at the low end. Nobody can promise nintedanib follows the identical curve. But it's the closest comparable, same disease, same specialty channel, and it suggests the ceiling on generic nintedanib pricing should come down substantially over the next year.
Savings tip: If you were prescribed Ofev before spring 2026, your prescription almost certainly says "Ofev" — not "nintedanib." Call your prescriber and ask whether generic substitution is appropriate for you now that multiple generics have launched. This one phone call is the highest-value thing most Ofev patients can do in 2026.
Why is Ofev so expensive?
Three things kept the price where it is, and two of them are now weakening.
It's an orphan drug. Idiopathic pulmonary fibrosis affects a relatively small population — roughly 100,000 people in the US. Drugs for rare diseases carry incentives including extended market exclusivity, and manufacturers price against a small patient base to recover development costs. Small market, high per-patient price.
There was no competition. From 2014 until April 2026, nintedanib had no generic equivalent in the US. Esbriet is the only other approved IPF therapy, and it works through a different mechanism — not a straight substitute your pharmacist can swap in.
Specialty distribution adds friction. Limited pharmacy networks, prior authorization, and step therapy requirements all sit between you and the medication. Most insurance plans do cover Ofev, but prior authorization is required for the large majority of enrollees, and commercial and ACA plans frequently require step therapy first.
The orphan-drug economics haven't changed. The other two are changing right now.
What Medicare's negotiated price does — and doesn't — do
Ofev was selected for Medicare drug price negotiation in the 2027 cycle. CMS settled on a Maximum Fair Price of $6,350 per month, effective January 1, 2027 — a 49.7% reduction from the list price, and a steeper discount than most drugs in that negotiation round received.
Two things to be clear about.
That price applies to Medicare Part D. If you're uninsured, paying cash, or on a commercial plan, the negotiated price is not your price. It may exert downward pressure on the market over time, but it doesn't hit your receipt on January 1.
And it's still $6,350 a month. Even after a near-50% cut on the largest price-negotiation program the US government has ever run, brand Ofev costs more per month than most American households earn. That's worth sitting with when you're deciding whether to pursue the generic or a cash-pay route.
How to save on Ofev in 2026
The levers here are different from a typical retail prescription, because a coupon at your neighborhood pharmacy doesn't apply to a specialty drug. These are the ones that move real money.
Ask specifically for generic nintedanib
Covered above, but it belongs at the top of any savings list. Multiple manufacturers, both strengths, approved and launching. Your prescriber and specialty pharmacy may not have volunteered this yet — generic availability information moves slowly through specialty channels. Ask directly, and ask more than once if the first answer is vague.
Compare cash-pay and cross-border pricing
Cash-pay networks price medications outside the US insurance system entirely, which is why the numbers look so different. International listings for nintedanib have appeared in the range of roughly $500 to $1,500 a month against US specialty pricing of $12,600 and up.
Cash-pay pricing works the same whether or not you have insurance, which makes it worth checking if you're uninsured, carrying a high-deductible plan, sitting in a coverage gap, or facing a prior authorization denial. Verify that any pharmacy you use is licensed and verified, and that a valid prescription is on file. Prices move, so confirm the current number before you order rather than relying on a figure you read somewhere.
Talk to your doctor about the pirfenidone route
This isn't a decision to make on your own, and the two drugs aren't interchangeable — they work through different pathways, have different side effect profiles, and suit different patients. Nintedanib's most common side effect is diarrhea; pirfenidone's tends to be nausea and photosensitivity.
But the cost difference is large enough that it deserves a conversation. Generic pirfenidone at roughly $597 a month retail — or a couple hundred with a discount — against brand Ofev at $12,600 is a gap no one should discover by accident. If your pulmonologist thinks either drug is clinically reasonable for you, cost is a legitimate factor in choosing between them.
Ask about 90-day fills
Specialty pharmacies will sometimes price a 90-day supply better than three monthly fills, and it cuts shipping costs and refill gaps. Not always available for specialty medications, and not always cheaper. Worth asking.
Use HSA, FSA, or HRA dollars
If you have a health savings account, flexible spending account, or health reimbursement arrangement, nintedanib is an eligible expense. Paying with pre-tax dollars effectively discounts the cost by your marginal tax rate. Keep receipts. FSA funds generally expire at the end of the plan year; HSA funds roll over.
Important: Do not stop taking nintedanib because of cost without talking to your doctor first. IPF is progressive, and lung function lost to a treatment gap does not come back. If you can't afford your next fill, tell your prescriber that plainly — before you skip it. There are usually more options than the specialty pharmacy mentioned on the first call.
What Ofev is and what it does
Some grounding, since the price only makes sense next to what you're buying.
Nintedanib is a tyrosine kinase inhibitor. It doesn't reverse lung scarring — nothing does — but it slows the decline in lung function, measured as forced vital capacity, in idiopathic pulmonary fibrosis. It's also approved for chronic fibrosing interstitial lung diseases with a progressive phenotype and for systemic sclerosis-associated ILD.
The standard dose is 150 mg twice daily, taken with food, about 12 hours apart. Some people take 100 mg twice daily instead, usually because of liver enzyme elevations or side effects they couldn't tolerate at the full dose.
Diarrhea is the most common side effect by a wide margin, affecting the majority of patients in clinical trials. Nausea, abdominal pain, decreased appetite, and weight loss are also common. Liver enzyme elevations require monitoring with regular blood work. Nintedanib carries bleeding risk and has been associated with arterial thromboembolic events, so tell your doctor about any blood thinners you take and about any history of cardiovascular disease.
It's taken indefinitely. That's why the monthly number matters so much more than it would for a two-week course of something.
The bottom line
Brand Ofev costs about $12,600 a month at list in 2026, and up to $16,000 at retail — but that's no longer the only number on the table. Generic nintedanib was approved in April 2026 and is reaching pharmacies now, Medicare's negotiated $6,350 price starts in January 2027 for Part D, and cash-pay routes have listed nintedanib far below US specialty pricing.
Start with one call to your prescriber asking about generic substitution. Then compare a verified cash-pay price against what your specialty pharmacy quoted. If you're weighing treatment options with your doctor anyway, ask where pirfenidone fits — the generic has already made that trip down the price curve.
Frequently asked questions
How much does Ofev cost per month without insurance?
Brand-name Ofev has a 2026 list price of about $12,600 per month for the standard 150 mg twice-daily dose. Reported retail cash prices run from roughly $13,475 to $16,019 for 60 capsules. Generic nintedanib and cash-pay channels price considerably lower.
Is there a generic version of Ofev?
Yes. The FDA approved generic nintedanib esylate capsules in 100 mg and 150 mg strengths in April 2026 from several manufacturers including Apotex, Cipla, Dexcel, Dr. Reddy's, and Sandoz. Launches are underway through specialty distribution. Ask your prescriber whether substitution is appropriate for you.
Why does Ofev cost so much?
It's an orphan drug for a rare disease, it had no generic competition in the US from 2014 until April 2026, and it's distributed only through specialty pharmacies. Orphan-drug pricing against a small patient population keeps the per-patient cost high.
Will Medicare's negotiated price lower what I pay?
Only if you're on Medicare Part D. The $6,350 monthly Maximum Fair Price takes effect January 1, 2027 and applies to Part D. People paying cash or covered by commercial insurance won't get that price directly, though broader market pressure may develop over time.
Is pirfenidone a cheaper alternative to nintedanib?
Generic pirfenidone is dramatically cheaper — roughly $597 for 270 tablets of the 267 mg strength versus more than $10,000 for brand Esbriet. But the two drugs work differently and have different side effect profiles, so this is a decision for your pulmonologist, not a straight substitution.
What happens if I stop taking nintedanib?
Lung function decline typically resumes at its untreated rate, and function already lost doesn't return. Never stop because of cost without telling your prescriber first — say so directly, and ask what options exist before you skip a fill.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.
